Tebipenem P Granules (Tebipenem) is an oral carbapenem antibiotic primarily indicated for the treatment of infectious diseases in children. As a novel broad-spectrum antibacterial agent, its clinical use must strictly adhere to medication guidelines.

Dosage and Administration, Recommended Dosage of Tebipenem P Granules (Tebipenem)

Standard Conventional Dosage

The conventional dosage regimen of Tebipenem P Granules for children is calculated based on body weight: 4 mg/kg per dose, twice daily, to be taken orally after meals.

This dosage design fully takes into account the physiological characteristics and drug metabolism profiles of pediatric patients.

Control of Treatment Course

In principle, the duration of administration of this product shall not exceed 7 days. To prevent the emergence of drug-resistant bacteria, the shortest course necessary for disease treatment should be adopted after confirming bacterial susceptibility.

Dosage Adjustment of Tebipenem P Granules (Tebipenem)

Scope for Dosage Increase

When necessary, the single dose can be increased to 6 mg/kg, but such adjustment must be carried out under close medical supervision and based on a comprehensive evaluation of treatment response.

Dosage Adjustment During Combination with Other Drugs

Co-administration with H2-receptor antagonists (e.g., famotidine) or antacids can reduce the peak plasma concentration by 40-60%. In such cases, the dosage needs to be adjusted accordingly to ensure therapeutic efficacy.

Medication in Special Populations for Tebipenem P Granules (Tebipenem)

Patients with Renal Insufficiency

Patients with severe renal impairment: Due to delayed excretion of tebipenem, dosage adjustment is required.

Patients with mild or moderate renal impairment: The risk of central nervous system adverse reactions is increased.

Special Considerations for Infants and Young Children

Children under 3 years old have a relatively high incidence of diarrhea and loose stools (incidence rate up to 34.6%).

Symptomatic treatment should be promptly administered when symptoms such as diarrhea occur.

Special attention should be paid to the reduction of carnitine levels, and vigilance should be maintained for hypoglycemic symptoms caused by hypocalcemia.

Medication Principles for Neonates

Clinical trials on the efficacy and safety in low birth weight infants and neonates have not been conducted, so extreme caution is required when using this product in such populations.

Medication Guidelines for Pregnant Women

Pregnant women or women of childbearing potential may use this product only when the therapeutic benefit outweighs the risk.

The use of antibiotics containing the penem structure in the late stage of pregnancy may cause neonatal hypocarnitinemia.

Patients with Special Diseases

Patients with a history of convulsive disorders such as epilepsy, or those with central nervous system diseases, may be more prone to central nervous system symptoms such as convulsions and disturbance of consciousness.